[go: up one dir, main page]

PE20050468A1 - Productos farmaceuticos que comprenden bisfosfonatos - Google Patents

Productos farmaceuticos que comprenden bisfosfonatos

Info

Publication number
PE20050468A1
PE20050468A1 PE2004000900A PE2004000900A PE20050468A1 PE 20050468 A1 PE20050468 A1 PE 20050468A1 PE 2004000900 A PE2004000900 A PE 2004000900A PE 2004000900 A PE2004000900 A PE 2004000900A PE 20050468 A1 PE20050468 A1 PE 20050468A1
Authority
PE
Peru
Prior art keywords
sodium
pharmaceutical products
include bisphosphonates
solution
daikyo
Prior art date
Application number
PE2004000900A
Other languages
English (en)
Inventor
Alexandra Glausch
Rolf Loffler
Jurgen Sigg
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34312464&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20050468(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20050468A1 publication Critical patent/PE20050468A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)

Abstract

REFERIDA A UNA FORMA FARMACEUTICA EN SOLUCION QUE COMPRENDE (A) UN ENVASE PLASTICO ESTERILIZABLE POR CALOR CONTENIENDO SOLUCION DE BISFOSFONATO, (B) UN REGULADOR BASICO DE PH DE NATURALEZA ORGANICA TAL COMO CITRATO DE SODIO, ACETATO DE SODIO, FOSFATO DE SODIO, ENTRE OTROS, Y CUYO VALOR DE PH ES DE PREFERENCIA 6.5, (C) UN AGENTE ISOTONIZANTE NO IONICO COMO UN MANITOL, GLICEROL, SORBITOL, ENTRE OTROS. DICHO PRODUCTO ES ANALIZABLE MEDIANTE CROMATOGRAFIA DE FASE INVERSA Y SU ENVASE ES UNA RESINA DAIKYO CZ, BOLSA PARA INFUSION, JERINGA SCHOTT TOPPAC, ENTRE OTROS
PE2004000900A 2003-09-18 2004-09-16 Productos farmaceuticos que comprenden bisfosfonatos PE20050468A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US50440203P 2003-09-18 2003-09-18

Publications (1)

Publication Number Publication Date
PE20050468A1 true PE20050468A1 (es) 2005-10-03

Family

ID=34312464

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2004000900A PE20050468A1 (es) 2003-09-18 2004-09-16 Productos farmaceuticos que comprenden bisfosfonatos

Country Status (23)

Country Link
US (1) US7932241B2 (es)
EP (1) EP1663314A2 (es)
JP (1) JP4802096B2 (es)
KR (1) KR101015718B1 (es)
CN (1) CN1852739A (es)
AR (1) AR045670A1 (es)
AU (1) AU2004271731B2 (es)
BR (1) BRPI0414562A (es)
CA (1) CA2536206C (es)
CO (1) CO5680461A2 (es)
EC (1) ECSP066419A (es)
IL (1) IL173766A (es)
IS (1) IS8351A (es)
MA (1) MA28078A1 (es)
MY (1) MY141763A (es)
NO (1) NO20061682L (es)
NZ (1) NZ545343A (es)
PE (1) PE20050468A1 (es)
RU (1) RU2358739C2 (es)
TN (1) TNSN06084A1 (es)
TW (1) TWI345977B (es)
WO (1) WO2005025551A2 (es)
ZA (1) ZA200601209B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY141763A (en) 2003-09-18 2010-06-30 Novartis Ag Pharmaceutical products comprising bisphosphonates
US20050119230A1 (en) * 2003-09-18 2005-06-02 Alexandra Glausch Pharmaceutical products comprising bisphosphonated
AU2007321109A1 (en) * 2006-11-17 2008-05-22 Besins Healthcare Liquid pharmaceutical compositions comprising a bisphosphonate compound
EP1923049A1 (en) * 2006-11-17 2008-05-21 Besins Healthcare Pharmaceutical compositions comprising a bisphosphonate compound
ES2666650T3 (es) * 2006-12-29 2018-05-07 OstéoQC Inc. Métodos para alterar el crecimiento óseo mediante la administración de antagonista o agonista de sost o wise
JP5607408B2 (ja) * 2009-04-03 2014-10-15 帝人ファーマ株式会社 アレンドロン酸含有注射剤
AU2010278860B2 (en) 2009-07-31 2016-05-26 Thar Pharma, Llc Crystallization method and bioavailability
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US8882740B2 (en) * 2009-12-23 2014-11-11 Stryker Trauma Gmbh Method of delivering a biphosphonate and/or strontium ranelate below the surface of a bone
EP2363111A1 (en) 2010-03-01 2011-09-07 Combino Pharm, S.L. Stable pharmaceutical composition comprising bisphosphonate
WO2011132826A1 (en) * 2010-04-19 2011-10-27 Snu R&Db Foundation Transdermal drug delivery system and pharmaceutical composition for preventing or treating bone diseases
US9340565B2 (en) 2010-11-24 2016-05-17 Thar Pharmaceuticals, Inc. Crystalline forms
EP2712611A1 (en) 2012-09-27 2014-04-02 B. Braun Melsungen AG Stabilized aqueous compositions of neuromuscular blocking agents
RU2506085C1 (ru) * 2013-01-30 2014-02-10 Федеральное бюджетное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" (ФБУН ГНЦ ВБ "Вектор") Тетраэтил-2-(2,2,6,6-тетраметилпиперидин-4-иламино)-этилен-1,1-бисфосфонат, обладающий противоопухолевой активностью
CN104721132B (zh) * 2013-12-21 2018-05-18 石药集团恩必普药业有限公司 一种唑来膦酸注射液及其制备方法
US10098813B2 (en) * 2014-09-03 2018-10-16 Sun Pharmaceutical Industries Limited Perfusion dosage form
GB201505347D0 (en) * 2015-03-27 2015-05-13 Salupont Consulting Ltd Sterilisation of s-nitrosothiols
CN105232451B (zh) * 2015-09-27 2019-02-05 青岛斯蒂朗机电设备有限公司 一种含有唑来膦酸的注射用组合物
ES2968415T3 (es) 2016-02-09 2024-05-09 Sun Pharmaceutical Ind Ltd Sistema de perfusión
US10195218B2 (en) 2016-05-31 2019-02-05 Grunenthal Gmbh Crystallization method and bioavailability
CN111655291A (zh) * 2017-08-28 2020-09-11 阿斯德拉有限责任公司 环糊精在涉及磷脂失调的疾病和病症中的用途
KR20200107927A (ko) * 2017-09-28 2020-09-16 아스데라 엘엘씨 인지질 조절장애를 수반하는 질환 및 장애에서의 시클로덱스트린의 용도
CN110161168B (zh) * 2018-02-12 2022-12-20 四川科伦药物研究院有限公司 唑来膦酸及其杂质的高效液相色谱检测方法
WO2021056020A1 (en) 2019-09-16 2021-03-25 Amgen Inc. Method for external sterilization of drug delivery device

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3776880D1 (de) * 1986-11-21 1992-04-02 Ciba Geigy Ag Neue substituierte alkandiphosphonsaeuren.
JP3672342B2 (ja) * 1994-09-26 2005-07-20 アステラス製薬株式会社 ビスホスホン酸又はその誘導体を含有する注射液とその安定化方法、及び注射液アンプル
FR2740686B1 (fr) * 1995-11-03 1998-01-16 Sanofi Sa Formulation pharmaceutique lyophilisee stable
GB0012209D0 (en) * 2000-05-19 2000-07-12 Novartis Ag Organic compounds
WO2002022136A1 (en) 2000-09-18 2002-03-21 F H Faulding & Co Limited Diphosphonate solutions
CA2445584A1 (en) 2001-05-02 2002-11-07 Sicor Inc. Injectable pamidronate disodium
CA2347330C (en) 2001-05-10 2002-03-12 Pharmaceutical Partners Of Canada Inc. Liquid injectable formulation of disodium pamidronate
MY141763A (en) 2003-09-18 2010-06-30 Novartis Ag Pharmaceutical products comprising bisphosphonates

Also Published As

Publication number Publication date
AR045670A1 (es) 2005-11-02
JP4802096B2 (ja) 2011-10-26
US7932241B2 (en) 2011-04-26
KR20060087568A (ko) 2006-08-02
CA2536206C (en) 2010-08-24
CA2536206A1 (en) 2005-03-24
MA28078A1 (fr) 2006-08-01
TW200522969A (en) 2005-07-16
TNSN06084A1 (en) 2007-10-03
RU2358739C2 (ru) 2009-06-20
NO20061682L (no) 2006-06-14
IL173766A (en) 2012-10-31
ECSP066419A (es) 2006-09-18
KR101015718B1 (ko) 2011-02-22
IS8351A (is) 2006-03-13
ZA200601209B (en) 2007-04-25
CO5680461A2 (es) 2006-09-29
AU2004271731A1 (en) 2005-03-24
US20070015736A1 (en) 2007-01-18
JP2007505861A (ja) 2007-03-15
TWI345977B (en) 2011-08-01
CN1852739A (zh) 2006-10-25
WO2005025551A3 (en) 2006-01-12
EP1663314A2 (en) 2006-06-07
AU2004271731B2 (en) 2008-07-24
MY141763A (en) 2010-06-30
NZ545343A (en) 2010-08-27
RU2006112596A (ru) 2007-11-10
IL173766A0 (en) 2006-07-05
WO2005025551A2 (en) 2005-03-24
BRPI0414562A (pt) 2006-11-07

Similar Documents

Publication Publication Date Title
PE20050468A1 (es) Productos farmaceuticos que comprenden bisfosfonatos
ES2198127T3 (es) Composiciones farmaceuticas autoclaveables que contienen un agente quelante.
ES2077530B1 (es) Procedimiento para la preparacion de productos farmaceuticos para curar enfermedades tumorales.
MX2008001620A (es) Productos medicos y formulaciones parenterales.
JP2013189450A5 (es)
AR063471A1 (es) Formulaciones para administracion parenteral de compuestos y sus usos
AR059723A2 (es) Composicion de altas dosis de ibandronato
BRPI0910341A2 (pt) dispositivo para conservação, preparação espontanea e administração de um principio ativo
ATE269056T1 (de) Hochwirksame dihydroergotaminhaltige arzneizusammensetzungen
JP6632495B2 (ja) 抗菌用組成物
MX2024010767A (es) Kit, formulacion y metodos de gliburida de baja sorcion.
MX2023010313A (es) Formulación y métodos de gliburida de baja sorción.
PE20130814A1 (es) Sales de benzimidazolil piridil eteres y formulaciones que las contienen
ES2099649T3 (es) Nueva composicion farmaceutica destinada para la fabricacion de un polvo estable que contiene, a titulo de ingrediente activo, una asociacion de acido acetilsalicilico y de metoclopramida.
AR066670A1 (es) Concentrado de esmolol
CL2015003717A1 (es) Producto para el cuidado oral que comprende dos composiciones almacenadas separadamente: la primera composicion comprende una fuente de calcio y una fuente de fosfato capaces de generar hidroxiapatita in situ, un agente espesante y un humectante, la segunda composicion es una fase acuosa continua que incluye un agente espesante, un humectante, y al menos 30% por peso de agua y menos de 2,5% de la fuente de fosfato; metodo de remineralizacion dental.
HRP20140622T4 (hr) Farmaceutski pripravak ibuprofena za injekciju
ES457805A1 (es) Un procedimiento para la preparacion de derivados de tiou- rea.
CO5271647A1 (es) Metodo para prevenir la diarrea
AU2020345336B2 (en) Pharmaceutical composition containing p-boronophenylalanine and method for producing same
US20160303008A1 (en) Antiperspirant/deodorant composition
JP6120766B2 (ja) 注射液製剤及びその製造方法
PE20060484A1 (es) Preparaciones farmaceuticas liquidas que comprenden un compuesto de benzhidril piperizina
AR010942A1 (es) Derivado de la piperidinilmetiloxazolidinona, los procedimientos para prepararlo, su empleo en la elaboracion de medicamentos, las preparacionesfarmaceuticas que lo contienen y un procedimiento para elaborar estas preparaciones farmaceuticas.
CN202875809U (zh) 一种遮光型非pvc包装袋保护体

Legal Events

Date Code Title Description
FC Refusal